David Moll
Endocrinology, Diabetes & Metabolism · Ansonia, CTNPI 1831186584
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 55 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in CT, where the typical reported total is $924.
Across 55 payments — averaging $16.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$195
- Boehringer Ingelheim$107
- AstraZeneca$66
- Amneal Pharmaceuticals LLC$65
- AbbVie$65
- Corcept Therapeutics$57
- plus $364 from 13 others
Across 4 payments — averaging $49,183 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$197K
What the payments were for
- Food & beverage$91099%
- Education$81%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 12 | $195 |
| Boehringer Ingelheim | 7 | $107 |
| AstraZeneca | 5 | $66 |
| Amneal Pharmaceuticals LLC | 3 | $65 |
| AbbVie | 4 | $65 |
| Corcept Therapeutics | 2 | $57 |
| Novo Nordisk | 3 | $51 |
| Tandem Diabetes Care, Inc. | 3 | $49 |
| Amgen | 2 | $39 |
| Insulet Corporation | 2 | $39 |
| Merck | 3 | $38 |
| Ascensia Diabetes Care US Inc. | 2 | $29 |
| Valeritas, Inc. | 1 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $15 |
| Pfizer | 1 | $14 |
| IBSA Pharma Inc. | 1 | $12 |
How this compares
$918 in reported general payments places this provider in the 45th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
See all endocrinology, diabetes & metabolism providers in Connecticut →
Other endocrinology, diabetes & metabolism in Ansonia
- Liqun SongAnsonia$6K
- Chi TangAnsonia$6K
- Egils BogdanovicsTorrington$608K
- Ania JastreboffNew Haven$536K
- Robert ObersteinHartford$516K
- Fadi Al-KhayerStorrs$489K
- Silvio InzucchiNew Haven$461K
- Philip GoldbergNew Haven$324K
- Kevan HeroldNew Haven$261K
- Joseph RosenblattNew Britain$235K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.